Dutch trial with Viagra halted after 11 babies die

2020-02-27 04:06:22    阅读:801993

AMSTERDAM (Reuters) - A Dutch trial with sildenafil, sold under the brand name Viagra, has been immediately halted after 11 babies of mothers using the

medication died, one of the participating hospitals sai

d on Tuesday. When the trial was stopped on Monday, roughly half of 183 pregnant women participating were taking sildenafil, the Amsterdam University’s Academic Medical Center (AMC) said. The study started in 2015 and involved 11 hospitals. It was designed to look at possible beneficial effects of increased blood flow to the placenta in mothers whose unborn babies were severely underdev

eloped. Around 15 women who took the medication have not yet given birth. “Previous studies have shown that sildenafil would have a positive effect on the growth of babies. The first results of the current study showed that the管家婆一句话赢大钱2019第114期 re may be adverse effects for t

he baby after birth,” the AMC said. Yet the results showed that 17 babies were born with lung conditions and 11 died. Among the roughly equal control group, just three babies had lung problems

and none died. Among the women taking sildenafil, 11 of the babies died

due to “a possibly related lung condition” that caused high blood pressure in the lungs and may have resulted from reduced oxygen levels. An interim analysis found that t

he chance of blood vessel disease in the lungs “appears to be greater and the chance o

f death after birth seems to have incre

ased. The researchers found no positive effect for th

e children on other outcomes,” the AMC said. Stephen Evans, a professor of pharmacoepidemiology at the London School of Hy

giene & Tropica

l Medicine, said the small number of trials with pregnant women has limited our knowledge of medicines in pregnant women. “There have been other studies in this area, both involving preliminary work using animals and using pregnant women, and there was no indication that the treatment was dangerous based on previous research,” he said. The drug was originally developed

by Pfizer but is now off patent and available as a generic. Pfizer had no immediate comment.